Your session is about to expire
← Back to Search
Treatment for Peripheral Nerve Sheath Tumor
Summary
Forty patients with pancreatic cancer, sarcoma and carcinoma of breast will receive DeltaRex-G intravenously at a dose of 1-4 x 10e11 colony forming units (cfu) or equivalent 0.6-1.8 x 10e10 RV copies per dose one to three times a week. DeltaRex-G may be given alone or with one or more FDA approved cancer therapies/immunotherapies. Based on previous Phase 1/2 US based clinical studies, DeltaRex-G does not suppress the bone marrow or cause serious organ dysfunction, and enhanced immune cell trafficking in tumors may cause the tumors to appear larger or new lesions to appear on CT, PET or MRI. Further, tumor stabilization/regression/remission may occur later during the treatment period. Therefore, DeltaRex-G will be continued regardless of CT, PET or MRI results if the patient has clinical benefit and does not have symptomatic disease progression.
- Peripheral Nerve Sheath Tumor
- Chondrosarcoma
- Soft Tissue Sarcoma
- Pancreatic Cancer
- Osteosarcoma
- Chordoma
- Sarcoma
- Breast Cancer
Timeline
Treatment Details
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger